3-Year Follow-Up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) Trial

JACC: Cardiovascular Interventions

Volumn 1, Issue 4, 2008, Pages 439-448

  Holmes Jr , David R ^a   Teirstein, Paul S ^b   Satler, Lowell ^c   Sketch Jr , Michael H ^d   Popma, Jeffery J ^e   Mauri, Laura ^e  

^a MAYO CLINIC   (United States)

^b SCRIPPS MEMORIAL HOSPITAL   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Patrick)   (United States)

Author keywords

bare metal stent restenosis; Cypher stent; vascular brachytherapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; RAPAMYCIN;

ARTICLE; BRACHYTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY RECANALIZATION; DRUG ELUTING STENT; EMERGENCY SURGERY; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; OUTCOMES RESEARCH; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REOPERATION; STATISTICAL SIGNIFICANCE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BRACHYTHERAPY; CARDIOVASCULAR AGENTS; CORONARY ARTERY BYPASS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; KAPLAN-MEIERS ESTIMATE; METALS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RECURRENCE; RISK ASSESSMENT; SIROLIMUS; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 49549111193     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2008.05.010     Document Type: Article

References (39)

1. Williams D.O., Abbott J.D., and Kip K.E. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover registry. Circulation 114 (2006) 2154-2162
2. Marroquin O.C., Selzer F., Mulukutla S.R., et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med 358 (2008) 342-352
3. Kastrati A., Mehilli J., Pache J., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
4. Waksman R., Ajani A.E., White R.L., et al. Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. N Engl J Med 346 (2002) 1194-1199
5. Waksman R., Raizner A.E., Yeung A.C., et al. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet 359 (2002) 551-557
6. Waksman R., White R.L., Chan R.C., et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 101 (2000) 2165-2171
7. Teirstein P.S., Massullo V., Jani S., et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 336 (1997) 1697-1703
8. Teirstein P.S., Massullo V., Jani S., et al. Three-year clinical and angiographic follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 101 (2000) 360-365
9. Leon M.B., Teirstein P.S., Moses J., et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 344 (2001) 250-256
10. Popma J.J., Suntharalingam M., Lansky A.J., et al. Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation 106 (2002) 1090-1096
11. Waksman R., Ajani A.E., White R.L., et al. Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Circulation 109 (2004) 340-344
12. Ruef J., Hofmann M., Storger H., and Haase J. Four-year results after brachytherapy for diffuse coronary in-stent restenosis: will coronary radiation therapy survive?. Cardiovasc Revasc Med 8 (2007) 170-174
13. Grise M.A., Mossuelo V., Joni S., et al. Five year clinical follow up after intracoronary radiation: results of a randomized clinical trial. Circulation 105 (2002) 2737-2740
14. Holmes Jr. D.R., Tierstein P., Satler L., et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents. the SISR randomized trial. JAMA 295 (2006) 1264-1273
15. Stone G.W., Ellis S.G., Cox D.A., et al. One year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS IV trial. Circulation 109 (2004) 1942-1947
16. Tanabe K., Serruys P.W., Grube E., et al. TAXUS III trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 107 (2003) 559-564
17. Schukro C., Syeda B., Kirisits C., et al. Randomized comparison between intracoronary beta-radiation brachytherapy and implantation of paclitaxel-eluting stents for the treatment of diffuse in-stent restenosis. Radiother Oncol 82 (2007) 18-23
18. Lee S.W., Park S.W., Park D.W., et al. Comparison of six-month angiographic and three-year outcomes after sirolimus-eluting stent implantation versus brachytherapy for bare metal in-stent restenosis. Am J Cardiol 100 (2007) 425-430
19. Brambilla N.M., Ferrario A., Repetto E., et al. Use of sirolimus-eluting stents for treatment of in-stent restenosis: long-term follow up. J Cardiovasc Med 8 (2007) 699-705
20. Commeau P., and Barragan P.T. ISR II study: a long-term evaluation of sirolimus-eluting stent in the treatment of patients with in-stent restenotic native coronary artery lesions. Catheter Cardiovasc Interv 66 (2005) 158-162
21. Neumann F.-J., Desmet W., Grube E., et al. Effectiveness and safety of sirolimus-eluting stents in the treatment of restenosis after coronary stent placement. Circulation 111 (2005) 2107-2111
22. Saia F., Lemos P.A., Hoye A., et al. Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv 62 (2004) 283-288
23. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., and Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 119 (2006) 1056-1061
24. Laarman G.J., Suttorp M.J., Dirksen M.T., et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355 (2006) 1105-1113
25. Camenzind E., Steg P.G., and Wijns W. A meta-analysis of first generation drug eluting stent programs. Circulation 115 (2007) 1440-1445
26. Lagerqvist B., James S.K., Stenestrand U., Lindbäck J., Nilsson T., and Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
27. Holmes Jr. D.R., Kereiakes D.J., Laskey W.K., et al. Thrombosis and drug-eluting stents: an objective appraisal. J Am Coll Cardiol 50 (2007) 109-118
28. Van Beusekom H.M.M., Saia F., Zindler J.D., et al. Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur Heart J 28 (2007) 974-979
29. Kastrati A., Dibra A., Eberle S., et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 294 (2005) 819-825
30. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
31. Kuiper K., Salem K.K.J., Rotevatn S., Mills J., and Nordrehaug J.E. Implementing a best-treatment strategy with intracoronary brachytherapy for in-stent restenosis in patients at high risk for recurrence. Cardiovasc Revasc Med 8 (2007) 9-14
32. Grines C.L., Bonow R.O., Casey Jr. D.E., et al., American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 49 (2007) 734-739
33. Brunner-La Rocca H.P., Kaiser C., Bernheim A., et al., BASKET Investigators. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitats Trial (BASKET): an 18-month analysis. Lancet 370 (2007) 1552-1559
34. Kaiser C., Brunner-La Rocca H.P., Buser P.T., et al., BASKET Investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomized Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366 (2005) 921-929
35. Mehran R., Dangas G., Abizaid A.S., et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100 (1999) 1872-1878
36. Doyle B., Rihal C.S., O'Sullivan C.J., et al. Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation 116 (2007) 2391-2398
37. Nayak A.K., Kawamura A., Nesto R.W., et al. Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J 70 (2006) 1026-1029
38. Chen M.S., John J.M., Chew D.P., Lee D.S., Ellis S.G., and Bhatt D.L. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 151 (2006) 1260-1264
39. Williams D.O., and Abbott D.O. Et tu, bare metal stent?. Circulation 116 (2007) 2363-2365